Targeting the renin angiotensin system for respiratory diseases

Area of Science:

• Pulmonary Medicine
• Cardiovascular Research
• Pharmacology

Background:

• The renin-angiotensin system (RAS) is crucial for blood pressure regulation.
• RAS dysregulation is linked to inflammation, oxidative stress, and fibrosis in lung diseases such as asthma, COPD, IPF, and ALI.
• Targeting RAS components presents a potential therapeutic strategy for respiratory diseases.

Purpose of the Study:

• To provide an updated overview of the RAS.
• To review and analyze recent research on targeting RAS components for respiratory disease treatment.
• To highlight the therapeutic potential and current limitations of RAS-targeted therapies in lung diseases.

Main Methods:

• Compilation and analysis of experimental and clinical studies on RAS in respiratory diseases.
• Review of pharmacological interventions targeting various RAS components (e.g., ACE, AT1R, ACE2, AT2R, Mas receptor).
• Evaluation of emerging pathways like alamandine/MRGPRD.

Main Results:

• Inhibition of pro-inflammatory RAS axes (renin, ACE, Ang II, AT1R) and activation of protective axes (ACE2, AT2R, Ang (1-7), Mas) show varied efficacy in preclinical and clinical settings.
• The alamandine/MRGPRD pathway demonstrates therapeutic promise.
• Understanding of RAS ligand-receptor interactions and signaling pathways needs further elucidation.

Conclusions:

• Targeting the RAS is a promising avenue for treating respiratory diseases.
• Preclinical findings for some RAS-targeted molecules are promising but require more robust clinical validation.
• Future research should prioritize translational human studies for RAS-based drug development in lung diseases.